Department of Health and Human Services
National Institutes of Health
Toggle navigation
Search
Home
About the Clinical Center
Clinical Trials & You
Participate in a Study
Referring a Patient
How to Search
Contact Us
Search the Studies
Go Back
Searched Result
141 Studies found from all possible combinations of your search terms. Select a protocol that you wish to review.
Protocol Number
Title
Protocol Status
Min-Max Age
Institute
Keywords
16-AA-0059
Characterization of Brain Amyloid-beta (A-beta) Retention During Wakefulness And Following Emergence From Sleep In Healthy Subjects
Completed Study; data analyses ongoing
18-40 Years
NIAAA
Alzheimer 16
001722-I
An Open-label, Single Arm Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Leniolisib in Pediatric Patients (Aged 1 to 6 Years) with APDS (Activated Phosphoinositide 3-Kinase Delta Syndrome) Followed by an Open-label Long-term Ext
Participants currently recruited/enrolled
3-6 Years
NIAID
16
001678-AT
Microneurographic Assessment of Peripheral Nerves in Healthy Volunteers and Individuals with Sensory Dysfunction Caused by Inherited Mutations in the PIEZO2 Gene
Recruitment has not started
18-100 Years
NCCIH
16
001635-H
Non-myeloablative Phase I/II Haploidentical HCT Study for Patients with Sickle Cell Disease, Including Compromised Organ Function
Participants currently recruited/enrolled
4-100 Years
NHLBI
16
001578-C
A Phase 1/2 Study of Tiragolumab (NSC# 827799, IND# 161266) and Atezolizumab (NSC# 783608, IND# 161266) in Patients with Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors
Participants currently recruited/enrolled
3-100 Years
NCI
16
001565-H
A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Sickle Cell Disease
Enrolling by Invitation
16-100 Years
NHLBI
16
001559-C
A Feasibility Multicenter Phase I Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
Recruitment has not started
18-120 Years
NCI
16
001538-C
A Phase II Study of Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma and Multicentric Castleman Disease
Participants currently recruited/enrolled
18-120 Years
NCI
16
001522-H
A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Single-Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Intravenous ZMA001 in Healthy Subjects
Participants currently recruited/enrolled
18-60 Years
NHLBI
16
001521-D
CALIBRATE: A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Encaleret Compared to Standard of Care in Participants with Autosomal Dominant Hypocalcemia Type 1 (ADH1)
Participants currently recruited/enrolled
16-99 Years
NIDCR
16
000744-HG
Development of Virtual Reality-based Interventions to Strengthen Cognitive Skillsets Related to Attention Deficit Hyperactivity Disorder (ADHD): A Pilot Phase I and Randomized Controlled Phase II Trial
Participants currently recruited/enrolled
10-16 Years
NHGRI
16
000740-CH
A Phase 3 Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Chronocort in the Treatment of Participants Aged 16 Years and Over with Congenital Adrenal Hyperplasia
Enrolling by Invitation
18-99 Years
NICHD
16
000687-I
VRC 322/DMID 21-0016: A Phase I, Dose Escalation, Open-Label Clinical Trial to Evaluate Safety, Tolerability and Immunogenicity of a Nipah Virus (NiV) mRNA Vaccine, mRNA-1215, in Healthy Adults
No longer recruiting/follow-up only
18-60 Years
NIAID
16
000686-CH
Intrathecal 2-Hydroxypropyl-Beta-Cyclodextrin for Neurological Decline in Patients with Niemann-Pick Disease Type C1
Participants currently recruited/enrolled
18-125 Years
NICHD
16
000665-DK
A Randomized Double-Blind Placebo-Controlled Study of the LEPR Agonist Antibody REGN4461 for the Treatment of Metabolic Abnormalities in Patients with Familial Partial Lipodystrophy
Completed Study; data analyses ongoing
18-90 Years
NIDDK
16
000460-I
A Randomized, Placebo-controlled Crossover Study to Assess the Safety of Administering a Second Dose of a COVID-19 mRNA Vaccine in Individuals Who Experienced a Systemic Allergic Reaction to an Initial Dose
Completed Study; data analyses ongoing
16-69 Years
NIAID
16
000411-CC
A Feasibility Pilot Study of a Virtual Education-Based Transition Intervention to Improve Transition Readiness in Adolescent and Young Adults with Congenital Adrenal Hyperplasia.
Participants currently recruited/enrolled
16-22 Years
CC
16
000406-AA
Addictions Neuroclinical Assessment
Enrolling by Invitation
18-99 Years
NIAAA
16
000277-C
Imaging and Biopsy of People with HIV-1 Undergoing Analytic Treatment Interruption
Participants currently recruited/enrolled
18-100 Years
NCI
16
000241-CH
Phase II Trial of Liraglutide (Saxenda(R), Novo Nordisk) in Adolescents with Obesity After Sleeve Gastrectomy: A Pilot Open-Label Study
Completed Study; data analyses ongoing
12-20 Years
NICHD
16
000123-CC
Evaluation of Atherosclerotic Plaques in Abdominal CT Studies
No longer recruiting/follow-up only
30-90 Years
CC
16
000115-C
A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants with Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants with Solid Tumors on PD1/PDL1 Inhibitor Therapy, Including Booster D
Completed Study; data analyses ongoing
18-125 Years
NCI
16
20-M-0082
Phase 1 Study: PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease
Participants currently recruited/enrolled
18-99 Years
NIMH
Alzheimer
20-H-0141
Long-term Follow-up of Subjects With Sickle Cell Disease Treated With Ex Vivo Gene Therapy Using Autologous Hematopoietic Stem Cells Transduced With a Lentiviral Vector
No longer recruiting/follow-up only
18-99 Years
NHLBI
16
20-DK-0079
A Randomized, Double-Blinded, Placebo-Controlled Study of REGN4661, A Leptin Receptor Agonist Antibody, In Patients with Generalized Lipodystrophy
Completed Study; data analyses ongoing
12-90 Years
NIDDK
16
20-D-0131
Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren's Syndrome; a Phase Ib-IIa Placebo-controlled Clinical Trial and Associated Mechanistic Studies
Participants currently recruited/enrolled
18-75 Years
NIDCR
16
20-D-0122
A Phase IIb, Open-label Dose-ranging Study Evaluating the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics, and Efficacy of CLTX-305 (encaleret) in Autosomal Dominant Hypocalcemia Type 1 (ADH1)
Completed Study; data analyses ongoing
16-100 Years
NIDCR
16
20-C-0069
A First-In-Human Phase I Single-Agent Dose-Escalation and Dose Expansion Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
Participants currently recruited/enrolled
18-125 Years
NCI
16
20-C-0062
A phase 1b Study of Nivolumab in Patients with Autoimmune Disorders and Advanced Malignancies (AIM-NIVO)
Participants currently recruited/enrolled
18-125 Years
NCI
16
20-AG-0087
Ketone ester effects on biomarkers of brain metabolism and cognitive performance in cognitively intact adults >= 55 years old. A double-blinded randomized controlled clinical trial
Participants currently recruited/enrolled
55-125 Years
NIA
Alzheimer
19-I-0140
A Phase 1 Evaluation of the Safety of Belimumab in People with Idiopathic CD4 Lymphopenia and Autoantibodies (Phoebe)
Participants currently recruited/enrolled
18-70 Years
NIAID
16
19-DK-0072
Non-Alcoholic Fatty Liver Disease, the Hepatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
Participants currently recruited/enrolled
18-125 Years
NIDDK
16
19-C-0016
Natural History and Biospecimen Acquisition Study for Children and Adults with Rare Solid Tumors
Participants currently recruited/enrolled
0-125 Years
NCI
16
19-C-0006
Phase II Trial Evaluating Nivolumab In Patients With IDH-Mutant Gliomas With And Without Hypermutator Phenotype
Participants currently recruited/enrolled
18-125 Years
NCI
16
19-AT-0089
Sensory Afferents for Deep Pressure Sensation
Completed Study; data analyses ongoing
18-50 Years
NCCIH
16
18-N-0083
ASPIRO: A Phase 1/2/3, Randomized, Open-Label, Ascending-Dose, Delayed-Treatment Concurrent Control Clinical Study to Evaluate the Safety and Efficacy of AT132, an AAV8-Delivered Gene Therapy in X-Linked Myotubular Myopathy (XLMTM) Patients
No longer recruiting/follow-up only
3-5 Years
NINDS
16
18-DA-N095
Just-In-Time Adaptive Interventions for Addictive Behaviors
Participants currently recruited/enrolled
18-75 Years
NIDA
16
18-C-0080
Feasibility and Preliminary Efficacy of an Enhanced Mindfulness Intervention for Children and Young Adults with High Grade or High-Risk Cancer and Their Caregivers: A Pilot Randomized Controlled Trial
Completed Study; data analyses ongoing
5-125 Years
NCI
16
16-N-0170
Effects of Prism Adaption and rTMS on Brain Connectivity and Visual Representation
Completed Study; data analyses ongoing
18-75 Years
NINDS
16
16-N-0166
Deep Brain Stimulation Surgery for Treatment of Focal Hand Dystonia
No longer recruiting/follow-up only
22-100 Years
NINDS
16
16-N-0114
The Effect of Corticosteroids on Inflammation at the Edge of Acute Multiple Sclerosis Plaques: An Investigator-Blinded Study
Participants currently recruited/enrolled
18-120 Years
NINDS
16
16-N-0072
A Pilot Study of Adoptive Cellular Immunotherapy for Progressive Multifocal Leukoencephalopathy with Ex Vivo Generated Polyomavirus-Specific T-cells
Completed Study; data analyses ongoing
18-125 Years
NINDS
16
16-N-0064
Cholinergic Receptor Imaging in Dystonia
Completed Study; data analyses ongoing
18-100 Years
NINDS
16
16-N-0058
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
Completed Study; data analyses ongoing
18-60 Years
NINDS
16
16-N-0055
The Pathological Basis of MRI Signal Changes in Multiple Sclerosis: A Longitudinal In Vivo-to-Postmortem Study
Participants currently recruited/enrolled
18-120 Years
NINDS
16
16-N-0041
Tumor Related Epilepsy
Participants currently recruited/enrolled
8-99 Years
NINDS
16
16-N-0031
An All-Night Functional Magnetic Resonance Imaging Sleep Study With Auditory Stimuli
Participants currently recruited/enrolled
18-34 Years
NINDS
16
16-I-0165
An open-label, non-randomized extension study to evaluate the long term safety, tolerability, efficacy and pharmacokinetics of CDZ173 (leniolisib) in patients with APDS/PASLI (Activated phosphoinositide 3-kinase delta syndrome/p110 delta-activating mutat
No longer recruiting/follow-up only
12-75 Years
NIAID
16
16-I-0078
Microbial, Immune, and Metabolic Perturbations by Antibiotics (MIME study)
Participants currently recruited/enrolled
18-49 Years
NIAID
16
16-I-0065
Screening for Alpha Globin Deletions
No longer recruiting/follow-up only
18-39 Years
NIAID
16
16-I-0053
A Multicenter Study of the Immunogenicity of Recombinant Vesicular Stomatitis Vaccine for Ebola-Zaire (rVSVdeltaG-ZEBOV GP) for Pre-Exposure Prophylaxis in Individuals at Potential Occupational Risk for Ebola Virus Exposure (PREPARE)
No longer recruiting/follow-up only
18-125 Years
NIAID
16
16-I-0039
Screening of Healthy Volunteers for Investigational Antimalarial Drugs, Malaria Vaccines, and Controlled Human Malaria Challenge
Participants currently recruited/enrolled
18-50 Years
NIAID
16
16-I-0032
High Dose Peripheral Blood Stem Cell Transplantation with Post Transplant Cyclophosphamide for Patients with Chronic Granulomatous Disease
No longer recruiting/follow-up only
4-65 Years
NIAID
16
16-HG-0156
The Natural History, Physiology, Microbiome and Biochemistry Studies of Propionic Acidemia
Participants currently recruited/enrolled
0-125 Years
NHGRI
16
16-HG-0026
New Technology and Child Health
Participants currently recruited/enrolled
18-120 Years
NHGRI
16
16-HG-0017
Genomic Services Research Program
Participants currently recruited/enrolled
0-105 Years
NHGRI
16
16-H-0144
Impact of Elastin Mediated Vascular Stiffness on End Organs
Participants currently recruited/enrolled
3-85 Years
NHLBI
16
16-H-0132
CADASIL Disease Discovery
Completed Study; data analyses ongoing
18-100 Years
NHLBI
16
16-H-0129
Study to Evaluate the Effect of Nicotinamide Riboside on Immunity
Completed Study; data analyses ongoing
18-39 Years
NHLBI
16
16-H-0085
Pilot Study to Evaluate the Effect of Fasting and Refeeding on T-Cell Fate
Completed Study; data analyses ongoing
21-37 Years
NHLBI
16
16-H-0074
Williams Syndrome (WS) and Supravalvar Aortic Stenosis (SVAS) DNA and Tissue Bank
Participants currently recruited/enrolled
0-85 Years
NHLBI
16
16-H-0063
Williams Syndrome Skin and Vascular Elasticity Study (WS-SAVE Study)
Completed Study; data analyses ongoing
1-70 Years
NHLBI
16
16-H-0019
High Image Matrix CT Reconstruction
Completed Study; data analyses ongoing
18-99 Years
NHLBI
16
16-EI-0169
A Pilot Study to Investigate Ustekinumab (STELARA) for the Treatment of Active Sight-Threatening Uveitis
Completed Study; data analyses ongoing
18-125 Years
NEI
16
16-EI-0134
Studies of the Natural History, Pathogenesis and Outcome of Ocular Disorders
Participants currently recruited/enrolled
0-100 Years
NEI
16
16-EI-0104
Clinical and Molecular Studies in Families with Inherited Eye Disease
Participants currently recruited/enrolled
4-120 Years
NEI
16
16-EI-0090
Natural History of Spinocerebellar Ataxia Type 7 (SCA7)
Participants currently recruited/enrolled
12-100 Years
NEI
16
16-EI-0046
Uveitis/Intraocular Inflammatory Disease Biobank (iBank)
Completed Study; data analyses ongoing
8-100 Years
NEI
16
16-EI-0024
Rod and Cone Mediated Function in Retinal Disease
Participants currently recruited/enrolled
5-100 Years
NEI
16
16-E-0157
CaREFREE Study (Calorie Restriction, Environment and Fitness: Reproductive Effects Evaluation Study)
Completed Study; data analyses ongoing
18-28 Years
NIEHS
16
16-E-0096
Cytochrome P450 Epoxygenase Pathway Regulation of Macrophage Function
Completed Study; data analyses ongoing
18-65 Years
NIEHS
16
16-E-0006
Investigating the Impact of Obesity on Pubertal Development in Girls
Participants currently recruited/enrolled
8-14 Years
NIEHS
16
16-DK-0173
MEASuRE: Metreleptin Effectiveness and Safety Registry
Participants currently recruited/enrolled
0-98 Years
NIDDK
16
16-DK-0143
Idiosyncratic Liver Injury Associated with Drugs (ILIAD): A Retrospective Study
Participants currently recruited/enrolled
18-100 Years
NIDDK
16
16-DK-0125
Evaluation of Adults with Endocrine-Related Conditions
Participants currently recruited/enrolled
18-100 Years
NIDDK
16
16-DK-0068
The Molecular, Cellular, and Genetic Characterization of Human Adipose Tissue and its Role in Metabolism
Participants currently recruited/enrolled
18-90 Years
NIDDK
16
16-DA-N140
Effects of a New Behavioral Intervention on Alcohol Craving and Drinking
Participants currently recruited/enrolled
21-65 Years
NIDA
16
16-DA-0080
A Novel Compound for Alcoholism Treatment: a Translational Strategy - Part II
Completed Study; data analyses ongoing
18-70 Years
NIDA
16
16-D-0040
Natural History of Craniofacial Anomalies and Developmental Growth Variants
Participants currently recruited/enrolled
2-100 Years
NIDCR
16
16-CH-0164
A Phase III Extension Study of Efficacy, Safety and Tolerability of Chronocort (Registered) in the Treatment of Congenital Adrenal Hyperplasia
Completed Study; data analyses ongoing
18-80 Years
NICHD
16
16-CH-0113
Evaluation of Children with Endocrine and Metabolic-Related Conditions
Participants currently recruited/enrolled
0-100 Years
NICHD
16
16-CH-0103
Evaluation of Patients with Genetic Disorders
Participants currently recruited/enrolled
0-125 Years
NICHD
16
16-CC-0168
Focus Groups to Determine Surrogates' Views Regarding Patient Preference Predictors
Completed Study; data analyses ongoing
18-90 Years
CC
16
16-CC-0162
Longitudinal Changes in the Oral and Gut Microbiome of Individuals with Alcohol Dependence
Completed Study; data analyses ongoing
18-125 Years
CC
16
16-CC-0149
Dopamine and Motor Learning in Cerebral Palsy
Participants currently recruited/enrolled
5-25 Years
CC
16
16-CC-0098
Pilot Study of Ultrasound Guided Focal Thermal Ablation of Prostate Cancer
Clinical hold/Recruitment or enrollment suspended
18-100 Years
CC
16
16-CC-0049
A Phase II Study Using LC Bead LUMI Radio-Opaque Embolic Beads to Detect and Characterize the Vascularity of Hepatic Tumors During Treatment with Transarterial Embolization (TAE) Alone or Combined with Thermal Ablation
Completed Study; data analyses ongoing
18-100 Years
CC
16
16-CC-0001
Evaluation of MiSeq for Microbial Identification in Specimens
No longer recruiting/follow-up only
2-125 Years
CC
16
16-C-0171
Phase I/II Study of Lenalidomide Combined with Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-Associated Large Cell Lymphoma
No longer recruiting/follow-up only
18-125 Years
NCI
16
16-C-0154
A Phase I/II Trial of T Cell Receptor Gene Therapy Targeting HPV-16 E7 for HPV-Associated Cancers
Participants currently recruited/enrolled
18-120 Years
NCI
16
16-C-0151
Evaluation of the Natural History of and Specimen Banking for Patients with Tumors of the Central Nervous System
No longer recruiting/follow-up only
18-125 Years
NCI
16
16-C-0138
Collection of Peripheral Blood Mononuclear Cells (PBMCs) from Healthy Subjects for the Expansion of T Cells for Adoptive Cell Therapy
Participants currently recruited/enrolled
18-120 Years
NCI
16
16-C-0135
A Pilot Study of Combined Immune Checkpoint Inhibition in combination with Ablative Therapies in Subjects with Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)
Completed Study; data analyses ongoing
18-125 Years
NCI
16
16-C-0131
A Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced with a CD70-Binding Chimeric Antigen Receptor to Patients with CD70-Expressing Cancers
Participants currently recruited/enrolled
18-72 Years
NCI
16
16-C-0128
A Phase I/II Study of Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination with Nab-Paclitaxel in Participants with Previously Treated Metastatic and/ or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors
Completed Study; data analyses ongoing
18-125 Years
NCI
16
16-C-0121
A Pilot Clinical Trial of Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma
Completed Study; data analyses ongoing
18-125 Years
NCI
16
16-C-0107
A Phase I/II Trial of EP0057, a Nanoparticle Camptothecin with Olaparib in Patients with Relapsed/Refractory Small Cell Lung, Bladder and Prostate Cancers
Participants currently recruited/enrolled
18-125 Years
NCI
16
16-C-0097
Phase 1 Trial of Panobinostat in Children with Diffuse Intrinsic Pontine Glioma
Completed Study; data analyses ongoing
2-21 Years
NCI
16
16-C-0094
A Phase 1/2 Study of Baricitinib, a JAK1/2 Inhibitor, in Chronic Graft-Versus-Host Disease (cGVHD) after Allogeneic Hematopoietic Stem Cell Transplantation (SCT)
Completed Study; data analyses ongoing
18-125 Years
NCI
16
16-C-0092
A Pilot Study of Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-mutated, Non-Small Cell Lung Cancer (NSCLC) After Treatment with Osimertinib (AZD9291, Tagrisso)
Completed Study; data analyses ongoing
18-125 Years
NCI
16
16-C-0088
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritonea
Completed Study; data analyses ongoing
18-125 Years
NCI
16
16-C-0087
Phase I Study of Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor in Combination with Cisplatin in Patients with Refractory Solid Tumors
Completed Study; data analyses ongoing
18-125 Years
NCI
16
16-C-0081
A Phase I Dose Escalation Trial of Re-Irradiation in Good Prognosis Recurrent Glioblastoma
Completed Study; data analyses ongoing
18-125 Years
NCI
16
16-C-0076
Prospective Screening for Patient Specific Genotypes and Phenotypes that Influence Drug Dosing and Trial Selection in Cancer Patients
Enrolling by Invitation
18-125 Years
NCI
16
16-C-0073
A Phase 2 Study of Olaparib and Cediranib for the Treatment of Recurrent Ovarian Cancer
Completed Study; data analyses ongoing
18-125 Years
NCI
16
16-C-0061
Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols
Participants currently recruited/enrolled
18-120 Years
NCI
16
16-C-0060
A Phase 1b/2 Study of alvelestat (MPH966), an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation
Participants currently recruited/enrolled
18-125 Years
NCI
16
16-C-0048
Docetaxel and Prostvac for Metastatic Castration Sensitive Prostate Cancer
Completed Study; data analyses ongoing
18-125 Years
NCI
16
16-C-0047
A Phase 1 Trial of Pomalidomide in Combination with Liposomal Doxorubicin in Patients with Advanced or Refractory Kaposi Sarcoma
No longer recruiting/follow-up only
18-125 Years
NCI
16
16-C-0043
Phase II Trial of the MEK1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate in Adults with Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas
No longer recruiting/follow-up only
18-125 Years
NCI
16
16-C-0035
Prostvac in Patients with Biochemically Recurrent Prostate Cancer
Completed Study; data analyses ongoing
18-125 Years
NCI
16
16-C-0034
A Phase II Trial of Oral Pazopanib plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) without Prior Bevacizumab Exposure and (B) after Failing Prior Bevacizumab
Completed Study; data analyses ongoing
18-125 Years
NCI
16
16-C-0027
A Prospective Randomized and Phase II Trial for Metastatic Melanoma Using Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
Clinical hold/Recruitment or enrollment suspended
18-70 Years
NCI
16
16-C-0011
A Phase I-II Trial of Everolimus and Sorafenib in Patients with Recurrent High-Grade Gliomas
Completed Study; data analyses ongoing
18-125 Years
NCI
16
16-C-0010
Care of the Prostate Cancer Patient and Prospective Procurement of Prostate Cancer Tissue
Participants currently recruited/enrolled
18-125 Years
NCI
16
16-C-0009
Phase II Trial of Carboplatin and Bevacizumab for the Treatment of Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial and Spinal Cord Ependymoma in Adults: A Multi-Center Trial
Completed Study; data analyses ongoing
18-125 Years
NCI
16
16-C-0003
Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies
Participants currently recruited/enrolled
4-75 Years
NCI
16
16-AT-0136
Effects of External Ear Stimulation on Pain Perception and Mood
Participants currently recruited/enrolled
18-50 Years
NCCIH
16
16-AT-0077
Clinical and Scientific Assessment of Pain and Painful Disorders
Participants currently recruited/enrolled
12-120 Years
NCCIH
16
16-AA-0037
Effect of Opioid Receptor Modulation on Alcohol Self-Administration and Neural Response to Alcohol Cues in Heavy Drinkers: Role of OPRM1 Gene Variation
Completed Study; data analyses ongoing
21-60 Years
NIAAA
16
15-EI-0038
A Phase I/IIa Study of RS1 Ocular Gene Transfer for X-linked Retinoschisis
Completed Study; data analyses ongoing
18-120 Years
NEI
16
15-C-0142
Acceptance and Commitment Training for Adolescents and Adults with Neurofibromatosis Type 1, Plexiform Neurofibromas, and Chronic Pain: A Phase III Clinical Trial
Completed Study; data analyses ongoing
16-59 Years
NCI
16
15-C-0078
Safety and Feasibility of Stem Cell Gene Transfer Following R-EPOCH for Non-Hodgkin Lymphoma in AIDS Patients Using Peripheral Blood Stem/Progenitor Cells Treated with a Lentivirus Vector-Encoding Multiple Anti-HIV RNAs
No longer recruiting/follow-up only
18-65 Years
NCI
16
15-AG-0123
Intermittent Calorie Restriction, Insulin Resistance, and Biomarkers of Brain Function
Completed Study; data analyses ongoing
55-70 Years
NIA
Alzheimer
14-EI-0064
Whole Exome and Whole Genome Sequencing for Genotyping of Inherited and Congenital Eye Conditions
Participants currently recruited/enrolled
0-120 Years
NEI
16
13-DK-0091
Combination Therapy of Pegylated Interferon Alfa-2a and Tenofovir DF versus Tenofovir DF Monotherapy in HBeAg-Positive and HBeAg-Negative Chronic Hepatitis B
Completed Study; data analyses ongoing
18-125 Years
NIDDK
16
13-D-0033
Oral Specimen and Data Acquisition Study of Subjects Requiring Third Molar Removal
Participants currently recruited/enrolled
16-50 Years
NIDCR
16
13-AG-0034
Phase I, Double-Blind, Placebo-Controlled, Ascending, Single-Dose, Safety, Tolerability and Pharmacokinetic Study of Bisnorcymserine (BNC), a Highly Selective Inhibitor of Butyrylcholinesterase, in Healthy Adult Volunteers
Completed Study; data analyses ongoing
55-125 Years
NIA
Alzheimer
12-HG-0022
Inherited Diseases, Caregiving, and Social Networks
Completed Study; data analyses ongoing
18-125 Years
NHGRI
Alzheimer
11-I-0057
Effect of Interferon Alpha 2b Intensification on HIV-1 Residual Viremia in Individuals Suppressed on Antiretroviral Therapy
Completed Study; data analyses ongoing
18-65 Years
NIAID
16
11-H-0134
A Pilot Study of a Thrombopoietin-Receptor Agonist (TPO-R Agonist), Eltrombopag, in Moderate Aplastic Anemia Patients
No longer recruiting/follow-up only
2-99 Years
NHLBI
16
11-D-0172
The Pathogenesis and Natural History of Sjogren's Disease
Participants currently recruited/enrolled
16-100 Years
NIDCR
16
11-C-0200
A Phase II Trial In Which Patients With Metastatic Alveolar Soft Part Sarcoma Are Randomized to Either Sunitinib or Cediranib Monotherapy, with Cross-Over at Disease Progression
No longer recruiting/follow-up only
16-120 Years
NCI
16
10-AG-0423
A Pilot Study of Exendin-4 in Alzheimer's Disease
Completed Study; data analyses ongoing
60-125 Years
NIA
Alzheimer
09-I-0184
Studies in the Pathogenesis of Systemic Capillary Leak Syndrome
Completed Study; data analyses ongoing
0-100 Years
NIAID
16
09-C-0024
A Phase I Study of Quadrivalent Human Papilloma Virus (HPV) (Types 6, 11, 16, 18) Recombinant Vaccine in HIV-Infected and HIV-Negative Pre-Adolescents, Adolescents and Young Adults
Completed Study; data analyses ongoing
12-26 Years
NCI
16
07-E-0012
Rituximab in the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM)
Completed Study; data analyses ongoing
2-125 Years
NIEHS
16
04-AR-0205
Progression of Spinal Fusion in Ankylosing Spondylitis
Completed Study; data analyses ongoing
18-125 Years
NIAMS
16
03-H-0170
Nonmyeloablative Allogeneic Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Severe Congenital Anemias Including Sickle Cell Disease (SCD) and B-Thalassemia
No longer recruiting/follow-up only
2-80 Years
NHLBI
16
03-AR-0131
Genetic Determinants of Ankylosing Spondylitis Severity - Longitudinal Study
Completed Study; data analyses ongoing
18-125 Years
NIAMS
16
94-C-0074
Treatment and Natural History Study of Lymphomatoid Granulomatosis
No longer recruiting/follow-up only
12-125 Years
NCI
16